CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023

CNS Pharmaceuticals, Inc.

2023-Q3 EPS reported -$4.05

Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.
Cash at Sept 30 was $0.9M; raised $2.6M in October via warrant/ATM; expects to fund operations through Q4 2023.
Enrollment in potentially pivotal Berubicin GBM study reached 239 patients; full enrollment expected Dec 2023.
Topline data from interim analysis expected in December 2023; 45 of 60 trial sites activated across US and Europe.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CNS Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 15, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2023 and recent operational highlights.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-008159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.